Eric L. Barker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Eric L. Barker has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Charles P. Kuntz
Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University College of Pharmacy, West Lafayette, IN 47907, United States
4 shared publicationsBruce Felts
Department of Biomedical Sciences, University of North Dakota School of Medicine and Health Sciences, Grand Forks, ND 58202, United States
2 shared publicationsEkaterina A. Placzek
Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, 575 Stadium Mall Drive, West Lafayette, IN 47904, United States
2 shared publicationsGregory H. Hockerman
Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University College of Pharmacy, West Lafayette, IN 47907, United States
2 shared publications- L. Keith Henry
Department of Biomedical Sciences, University of North Dakota School of Medicine and Health Sciences, Grand Forks, ND 58202, United States
2 shared publications Natalie R. Sealover
Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University College of Pharmacy, West Lafayette, IN 47907, United States
2 shared publications
Latest Publications
- Open Access
- 26 September 2019
- Published by MDPI AG in Brain Sciences
- Vol. 9 (10) , 254
Endocannabinoids and Fear-Related Behavior in Mice Selectively Bred for High or Low Alcohol Preference
Alcohol use disorders (AUDs) have a high incidence of co-morbidity with stress-related psychopathologies, such as post-traumatic stress disorder (PTSD). Genetic and pharmacological studies support a prominent role for the endocannabinoid system (ECS) in modulating stress-related behaviors relevant to AUDs and PTSD. Mouse lines selectively bred for high (HAP) and low (LAP) alcohol preference show reproducible differences in fear-potentiated startle (FPS), a model for PTSD-related behavior. The first experiment in this study assessed levels of the endocannabinoids, anandamide (AEA) and sn-2 arachidonylglycerol (2-AG), in the prefrontal cortex (PFC), amygdala (AMG), and hippocampus (HIP) of male and female HAP1 and LAP1 mice following the expression of FPS to determine whether ECS responses to conditioned-fear stress (FPS) were correlated with genetic propensity toward high or low alcohol preference. The second experiment examined effects of a cannabinoid receptor type 1 agonist (CP55940) and antagonist (rimonabant) on the expression of FPS in HAP1 and LAP1 male and female mice. The estrous cycle of females was monitored throughout the experiments to determine if the expression of FPS differed by stage of the cycle. FPS was greater in male and female HAP1 than LAP1 mice, as previously reported. In both experiments, LAP1 females in diestrus displayed greater FPS than LAP1 females in metestrus and estrus. In the AMG and HIP, AEA levels were greater in male fear-conditioned HAP1 mice than LAP1 mice. There were no line or sex differences in effects of CP55940 or rimonabant on the expression of FPS. However, surprisingly, evidence for anxiogenic effects of prior treatment with CP55940 were seen in all mice during the third drug-free FPS test. These findings suggest that genetic differences in ECS function in response to fear-conditioning stress may underlie differences in FPS expression in HAP1 and LAP1 selected lines.
- 26 September 2019
- Published by MDPI AG in Brain Sciences
- Vol. 9 (10) , 254
Open AccessEndocannabinoids and Fear-Related Behavior in Mice Selectively Bred for High or Low Alcohol Preference
Alcohol use disorders (AUDs) have a high incidence of co-morbidity with stress-related psychopathologies, such as post-traumatic stress disorder (PTSD). Genetic and pharmacological studies support a prominent role for the endocannabinoid system (ECS) in modulating stress-related behaviors relevant to AUDs and PTSD. Mouse lines selectively bred for high (HAP) and low (LAP) alcohol preference show reproducible differences in fear-potentiated startle (FPS), a model for PTSD-related behavior. The first experiment in this study assessed levels of the endocannabinoids, anandamide (AEA) and sn-2 arachidonylglycerol (2-AG), in the prefrontal cortex (PFC), amygdala (AMG), and hippocampus (HIP) of male and female HAP1 and LAP1 mice following the expression of FPS to determine whether ECS responses to conditioned-fear stress (FPS) were correlated with genetic propensity toward high or low alcohol preference. The second experiment examined effects of a cannabinoid receptor type 1 agonist (CP55940) and antagonist (rimonabant) on the expression of FPS in HAP1 and LAP1 male and female mice. The estrous cycle of females was monitored throughout the experiments to determine if the expression of FPS differed by stage of the cycle. FPS was greater in male and female HAP1 than LAP1 mice, as previously reported. In both experiments, LAP1 females in diestrus displayed greater FPS than LAP1 females in metestrus and estrus. In the AMG and HIP, AEA levels were greater in male fear-conditioned HAP1 mice than LAP1 mice. There were no line or sex differences in effects of CP55940 or rimonabant on the expression of FPS. However, surprisingly, evidence for anxiogenic effects of prior treatment with CP55940 were seen in all mice during the third drug-free FPS test. These findings suggest that genetic differences in ECS function in response to fear-conditioning stress may underlie differences in FPS expression in HAP1 and LAP1 selected lines.
- 1 January 2018
- Published by Elsevier in Biochemical Pharmacology
- Vol. 147, 9
Corrigendum to “The external gate of the human and Drosophila serotonin transporters requires a basic/acidic amino acid pair for 3,4-methylenedioxymethamphetamine (MDMA) translocation and the induction of substrate efflux” [Biochem. Pharmacol. 120 (2016) 46–55]
- 1 January 2018
- Published by Elsevier in Biochemical Pharmacology
- Vol. 147, 9
Corrigendum to “The external gate of the human and Drosophila serotonin transporters requires a basic/acidic amino acid pair for 3,4-methylenedioxymethamphetamine (MDMA) translocation and the induction of substrate efflux” [Biochem. Pharmacol. 120 (2016) 46–55]
- 3 November 2010
- Published by Springer Nature
- p. 169-193
Monoamine Transporter Pathologies
- 1 November 2010
- Published by Elsevier in Biochemical Pharmacology
- Vol. 80 (9) , 1418-1426
Conformational flexibility of transmembrane helix VII of the human serotonin transporter impacts ion dependence and transport
- 1 November 2010
- Published by Elsevier in Biochemical Pharmacology
- Vol. 80 (9) , 1418-1426
Conformational flexibility of transmembrane helix VII of the human serotonin transporter impacts ion dependence and transport
- 1 August 2010
- Published by Elsevier in Neurochemistry International
- Vol. 57 (1) , 76-83
Activation of TRPC6 channels promotes endocannabinoid biosynthesis in neuronal CAD cells
- 1 August 2010
- Published by Elsevier in Neurochemistry International
- Vol. 57 (1) , 76-83
Activation of TRPC6 channels promotes endocannabinoid biosynthesis in neuronal CAD cells
- Open Access
- 1 May 2010
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 285 (20) , 15369-15379
Structural Analysis of the Extracellular Entrance to the Serotonin Transporter Permeation Pathway
- 1 May 2010
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 285 (20) , 15369-15379
Open AccessStructural Analysis of the Extracellular Entrance to the Serotonin Transporter Permeation Pathway
- 1 April 2010
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 53 (3) , 567-575
Lipidomic metabolism analysis of the endogenous cannabinoid anandamide (N-arachidonylethanolamide)
- 1 April 2010
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 53 (3) , 567-575
Lipidomic metabolism analysis of the endogenous cannabinoid anandamide (N-arachidonylethanolamide)
- Open Access
- 1 July 2009
- Published by Elsevier in Molecular Pharmacology
- Vol. 76 (1) , 11-17
Inactivation and Biotransformation of the Endogenous Cannabinoids Anandamide and 2-Arachidonoylglycerol
The cannabinoid field is currently an active research area. Anandamide (AEA) and 2-arachidonoylglycerol (2-AG) are the most characterized endogenous cannabinoids (also known as endocannabinoids). These neuromodulators have been implicated in various physiologically relevant phenomena, including mood (Witkin et al., 2005), the immune response (Ashton, 2007), appetite (Kirkham and Tucci, 2006), reproduction (Wang et al., 2006), spasticity (Pertwee, 2002), and pain (Hohmann and Suplita, 2006). Pharmacological manipulation of AEA and 2-AG signaling should prove to have significant therapeutic applications in disorders linked to endocannabinoid signaling. One way to alter endocannabinoid signaling is to regulate the events responsible for termination of the endocannabinoid signal-cellular uptake and metabolism. However, to pharmacologically exploit AEA and/or 2-AG signaling in this way, we must first gain a better understanding of the proteins and mechanisms governing these processes. This review serves as an introduction to the endocannabinoid system with an emphasis on the proteins and events responsible for the termination of AEA and 2-AG signaling.
- 1 July 2009
- Published by Elsevier in Molecular Pharmacology
- Vol. 76 (1) , 11-17
Open AccessInactivation and Biotransformation of the Endogenous Cannabinoids Anandamide and 2-Arachidonoylglycerol
The cannabinoid field is currently an active research area. Anandamide (AEA) and 2-arachidonoylglycerol (2-AG) are the most characterized endogenous cannabinoids (also known as endocannabinoids). These neuromodulators have been implicated in various physiologically relevant phenomena, including mood (Witkin et al., 2005), the immune response (Ashton, 2007), appetite (Kirkham and Tucci, 2006), reproduction (Wang et al., 2006), spasticity (Pertwee, 2002), and pain (Hohmann and Suplita, 2006). Pharmacological manipulation of AEA and 2-AG signaling should prove to have significant therapeutic applications in disorders linked to endocannabinoid signaling. One way to alter endocannabinoid signaling is to regulate the events responsible for termination of the endocannabinoid signal-cellular uptake and metabolism. However, to pharmacologically exploit AEA and/or 2-AG signaling in this way, we must first gain a better understanding of the proteins and mechanisms governing these processes. This review serves as an introduction to the endocannabinoid system with an emphasis on the proteins and events responsible for the termination of AEA and 2-AG signaling.
- Open Access
- 21 October 2008
- Published by Wiley in Journal of Neurochemistry
- Vol. 107 (4) , 987-1000
Mechanisms for recycling and biosynthesis of endogenous cannabinoids anandamide and 2‐arachidonylglycerol
The mechanisms of endogenous cannabinoid biosynthesis are not completely understood. We hypothesized that anandamide could be recycled by the cell to form new endocannabinoid molecules and released into the extracellular space. We determined that new endocannabinoids derived from exogenous anandamide or arachidonic acid were synthesized and released from RBL‐2H3 cells in response to ionomycin. Treatment of RBL‐2H3 cells with nystatin and progesterone, agents that disrupt organization of lipid raft/caveolae, resulted in the attenuation of anandamide and 2‐arachidonyl glycerol synthesis and/or release in response to stimulation with ionomycin suggesting a role for these membrane microdomains in endocannabinoid biosynthesis. Furthermore, anandamide synthesis may be independent ofN‐acyl phosphatidylethanolamine phospholipase D as expression of the enzyme was not detected in RBL‐2H3 cells. We also established that extracellular calcium is necessary for endocannabinoid biosynthesis because release of intracellular calcium stores alone does not promote endocannabinoid biosynthesis. Next, we examined the role of calcium as a ‘switch’ to activate the synthesis of anandamide and simultaneously reduce uptake. Indeed, [3H] anandamide uptake was reduced in the presence of calcium. Our findings suggest a mechanism indicative of calcium‐modulated activation of anandamide synthesis and simultaneous termination of uptake.
- 21 October 2008
- Published by Wiley in Journal of Neurochemistry
- Vol. 107 (4) , 987-1000
Open AccessMechanisms for recycling and biosynthesis of endogenous cannabinoids anandamide and 2‐arachidonylglycerol
The mechanisms of endogenous cannabinoid biosynthesis are not completely understood. We hypothesized that anandamide could be recycled by the cell to form new endocannabinoid molecules and released into the extracellular space. We determined that new endocannabinoids derived from exogenous anandamide or arachidonic acid were synthesized and released from RBL‐2H3 cells in response to ionomycin. Treatment of RBL‐2H3 cells with nystatin and progesterone, agents that disrupt organization of lipid raft/caveolae, resulted in the attenuation of anandamide and 2‐arachidonyl glycerol synthesis and/or release in response to stimulation with ionomycin suggesting a role for these membrane microdomains in endocannabinoid biosynthesis. Furthermore, anandamide synthesis may be independent ofN‐acyl phosphatidylethanolamine phospholipase D as expression of the enzyme was not detected in RBL‐2H3 cells. We also established that extracellular calcium is necessary for endocannabinoid biosynthesis because release of intracellular calcium stores alone does not promote endocannabinoid biosynthesis. Next, we examined the role of calcium as a ‘switch’ to activate the synthesis of anandamide and simultaneously reduce uptake. Indeed, [3H] anandamide uptake was reduced in the presence of calcium. Our findings suggest a mechanism indicative of calcium‐modulated activation of anandamide synthesis and simultaneous termination of uptake.